复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02196 复星医药

休市中 12-19 16:08:06

21.080

+0.460

+2.23%

最高21.100	最低20.420	成交量457.01万
今开20.500	昨收20.620	日振幅3.30%
总市值560.52亿	流通市值114.04亿	总股本26.59亿
成交额9,572万	换手率0.84%	流通股本5.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":21.08,"timestamp":1766131686005,"preClose":20.62,"halted":0,"volume":4570108,"delay":0,"floatShares":540971500,"shares":2659000000,"eps":1.1478790837995783,"marketStatus":"休市中","change":0.46,"latestTime":"12-19 16:08:06","open":20.5,"high":21.1,"low":20.42,"amount":95718633,"amplitude":0.032978,"askPrice":21.08,"askSize":70000,"bidPrice":21.02,"bidSize":500,"shortable":3,"etf":0,"ttmEps":1.3698539581663542,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":7,"adr":0,"listingDate":1351526400000,"exchange":"SEHK","adjPreClose":20.62,"dividendRate":0.016776,"openAndCloseTimeList":[[1766107800000,1766116800000],[1766120400000,1766131200000]],"volumeRatio":0.6855804800124372,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":27.27,"timestamp":1766127600000,"preClose":26.68,"halted":0,"volume":18686200,"delay":0,"premium":"-30.15"}},"requestUrl":"/m/hq/s/02196","defaultTab":"news","newsList":[{"id":"2592577131","title":"复星医药：控股子公司药品获美国FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2592577131","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592577131?lang=zh_cn&edition=full","pubTime":"2025-12-19 17:20","pubTimestamp":1766136033,"startTime":"0","endTime":"0","summary":"南方财经12月19日电，复星医药(600196.SH)公告称，控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司获美国FDA批准开展HLX18（重组抗PD-1人源化单克隆抗体注射液）用于治疗多种实体瘤的I期临床试验。复宏汉霖拟于条件具备后于美国开展该药品的I期临床试验。HLX18是复星医药自主研发的纳武利尤单抗生物类似药，拟用于多种癌症的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512193596838564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0196","BK0028","600196","BK0188","BK1191","BK0012","BK1515","BK0175","BK0096","BK0239","BK1593","02196","BK0183","BK0060","BK0187"],"gpt_icon":0},{"id":"2592999481","title":"复星医药双线突围：14亿押注争议药物，全球合作对冲研发风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2592999481","media":"投资时报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592999481?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:52","pubTimestamp":1766134346,"startTime":"0","endTime":"0","summary":"评估报告显示，截至2025年9月30日，绿谷医药股东全部权益的评估值为16.74亿元。为了应对挑战，复星医药正持续加大向创新药的转型力度。就在市场将焦点投向绿谷医药的同时，复星医药的全球布局仍在提速。12月18日，复星医药宣布其控股子公司复星医药产业与美国Clavis Bio公司签订《合作及选择权协议》，双方将共同选定靶点推进临床前药物开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219165312a45f4c19&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219165312a45f4c19&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1191","BK1593","BK1515"],"gpt_icon":0},{"id":"2592619994","title":"每日卖空追踪 | 复星医药 12月19日卖空量成交14.25万股，卖空比例为3.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592619994","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592619994?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:30","pubTimestamp":1766133027,"startTime":"0","endTime":"0","summary":"复星医药北京时间12月19日，涨2.23%，卖空量成交14.25万股，较上一交易日增加22.84%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219163425a45f3590&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219163425a45f3590&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","02196","BK1191","BK1515"],"gpt_icon":0},{"id":"2592819915","title":"复星医药12月19日主力净流入272.3万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2592819915","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592819915?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:15","pubTimestamp":1766132145,"startTime":"0","endTime":"0","summary":"12月19日, 复星医药股价涨2.23%，报收21.08元，成交金额9571.9万元，换手率0.84%，振幅3.30%，量比0.68。复星医药今日主力资金净流入272.3万元，上一交易日主力净流出7.3万元。该股近5个交易日下跌5.33%，主力资金累计净流出2684.4万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入312.9万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219161951a45f22d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219161951a45f22d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1191","BK1593","BK1515"],"gpt_icon":0},{"id":"2592513686","title":"【券商聚焦】交银国际：临近年末 续看好新BD交易集中落地机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2592513686","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592513686?lang=zh_cn&edition=full","pubTime":"2025-12-19 09:20","pubTimestamp":1766107245,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际发布医药行业周报，本周多项超10亿美元的BD交易相继落地，合作伙伴既有MNC也有中小型生物科技公司。临近年末，该机构继续看好新BD交易集中落地机会。展望2026 年，该机构认为板块稳中向好态势延续，但影响市场表现的核心因素或呈分化态势，后续选股逻辑或将重回基本面和估值，即关注存在基本面预期差、当前仍被低估的个股。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971853","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0540923850.HKD","LU0588546209.SGD","LU1303224171.USD","BK1191","LU0634319403.HKD","02228","LU1115378108.SGD","IE00B5MMRT66.SGD","09926","02367","BK1197","BK1583","LU0417516902.SGD","LU1251922891.USD","01530","LU0348825331.USD","LU1720050803.USD","LU0348784397.USD","01789","06160","01099","BK1500","IE00B543WZ88.USD","LU0348783233.USD","LU2328871848.SGD","BK1588","LU0417516738.SGD","LU0348766576.USD","BK1147","LU2476274720.SGD","02196","03329","HK0000165453.HKD","LU2399975544.HKD","02268","03933","BK1585","LU2778985437.USD","LU0561508036.HKD","BK1617","BK1593","SG9999014674.SGD","LU1770034418.SGD","09688","LU0348735423.USD","LU1794554557.SGD","LU2488822045.USD","LU0417516571.SGD","LU2476274308.USD","LU0307460666.USD"],"gpt_icon":0},{"id":"2592199155","title":"复星一周两次落子汉正街 补缺“外滩中心”","url":"https://stock-news.laohu8.com/highlight/detail?id=2592199155","media":"观点","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592199155?lang=zh_cn&edition=full","pubTime":"2025-12-19 07:31","pubTimestamp":1766100660,"startTime":"0","endTime":"0","summary":"一周之内，两场落槌，复星在汉正街约投入26亿元。本次土拍最受关注的焦点，无疑是复星集团在汉正街的再度加码。据市场分析，复星并非简单的规模扩张，而是基于“复星外滩中心”项目整体规划调整后的资产确权。三年后的2017年1月，复星进一步扩大版图，斥资130.1亿元竞得汉正街东片核心地块，正式确立了“复星外滩中心”百万方大盘格局，并计划在此引入金融蜂巢产业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219131040a45e77f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219131040a45e77f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1593","BK1515","BK1191"],"gpt_icon":0},{"id":"2592906229","title":"官宣9款医疗险覆盖商保创新药后又撤销，复星联合健康保险缘何“悔棋”","url":"https://stock-news.laohu8.com/highlight/detail?id=2592906229","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592906229?lang=zh_cn&edition=full","pubTime":"2025-12-18 20:55","pubTimestamp":1766062500,"startTime":"0","endTime":"0","summary":"　　多天前，首版《商业健康保险创新药品目录》公布，目录中19种创新药被正式推向了商业健康保险的舞台中央。业内正翘首以待，谁会将目录中的创新药纳入保险保障，成为第一批“吃螃蟹”的保险机构。一则“官宣！复星联合健康保险9款医疗险覆盖商保创新药！”复星联合健康保险的官宣无疑令业内欣喜。　　复星联合健康保险“悔棋”动作的背后，与首次推出的《商业健康保险创新药品目录》不无关联。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-12-18/doc-inhcfrcf8430514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BJJMRY28.SGD","LU2244417387.USD","LU0795875169.SGD","LU0912757837.SGD","LU1064131342.USD","LU0320765059.SGD","LU0079474960.USD","LU0310800379.SGD","LU2028103732.USD","BK4588","LU2347655156.SGD","LU1670627923.USD","LU1791710582.SGD","LU0708995401.HKD","LU1057294990.SGD","LU1548497426.USD","LU0345770993.USD","LU1119994496.HKD","IE0009355771.USD","SG9999018865.SGD","LU0149725797.USD","SGXZ51526630.SGD","LU1914381329.SGD","LU2264538146.SGD","LU2089984988.USD","LU0029864427.USD","LU1035773651.USD","BK4154","LU1061106388.HKD","LU0158827948.USD","IE00BN29S564.USD","LU1084165304.USD","LU2468319806.SGD","LU0823416689.USD","LU1988902786.USD","LU1023059063.AUD","LU1670628061.USD","LU0128525929.USD","SG9999014898.SGD","LU1003077747.HKD","IE00B19Z9P08.USD","IE00B1BXHZ80.USD","LU2361044865.SGD","LU0289739699.SGD","LU2087625088.SGD","BK1161","LU0861579265.USD","LU2362541513.USD","LU2552382215.SGD","LU0052756011.USD","IE00BZ1G4Q59.USD","LU2361044949.HKD","LU0738911758.USD","LU0976567544.SGD","SG9999014914.USD","LU0077335932.USD","LU0820562030.AUD","BK4532","IE00B19Z3581.USD","LU2360032135.SGD","LU0053666078.USD","LU1674673428.USD","LU2491050071.SGD","LU2023251221.USD","IE00BJT1NW94.SGD","LU1153585028.USD","SGXZ81514606.USD","SG9999018857.SGD","LU0661504455.SGD","IE00B19Z8X17.USD","LU2211815571.USD","LU0708994859.HKD","LU0310799852.SGD","LU0353189763.USD","LU1854103824.USD","SG9999001176.USD","LU0310800965.SGD","LU0417517546.SGD","LU1267930730.SGD","LU2362541273.HKD","IE000M9KFDE8.USD","LU0114720955.EUR","LU2324357040.USD","LU2461242641.AUD","LU0787776722.HKD","LU1674673691.USD","LU0203347892.USD","LU1720051108.HKD","LU2125154935.USD","LU0456855351.SGD","LU2236285917.USD","LU2089284900.SGD","LU0107464264.USD","LU0342679015.USD","LU0432979614.USD","LU0211327993.USD","LU0203345920.USD","LU2125154778.USD","SG9999002232.USD","IE00BWXC8680.SGD","LU0820561818.USD","IE00B2B36J28.USD","LU0553294199.USD","SG9999017495.SGD","LU0158827781.USD","LU1066053197.SGD","BK4533","LU1551013342.USD","LU2357305700.SGD","BK1574","LU2361045086.USD","LU0965508806.USD","IE0005OL40V9.USD","LU0496365809.HKD","LU0251132253.USD","LU0557290698.USD","LU0672654240.SGD","LU1732799900.SGD","SG9999002224.SGD","IE00B894F039.SGD","IE00B7SZLL34.SGD","LU0820561909.HKD","LU2133065610.SGD","IE00B1XK9C88.USD","BK4566","IE0002270589.USD","LU0354030511.USD","IE00BFTCPJ56.SGD","LU1323610961.USD","LU0943347566.SGD","LU1983299246.USD","IE0004445015.USD","LU0128525689.USD","IE00B19Z9Z06.USD","BK4581","LU0882574055.USD","LU1069347547.HKD","LU0965509010.AUD","LU1291159041.SGD","LU2552382058.USD","SG9999001176.SGD","SG9999013999.USD","IE00B7KXQ091.USD","LU0238689110.USD","LU0689472784.USD","LU1267930227.SGD","LU1261432733.SGD","LU1934455863.HKD","SGXZ57979304.SGD","LU0545039389.USD","LU0187121727.USD","IE00BJJMRZ35.SGD","LU1496350502.SGD","IE00BKVL7J92.USD","LU0058720904.USD","LU0256863811.USD","BK4585","LU1267930490.SGD","LU0198837287.USD","LU0122379950.USD","IE0004445239.USD","LU2552382132.HKD","LU0345770308.USD","LU1551013425.SGD","LU0354030438.USD","LU0965509101.SGD","LU1732800096.USD","LU1778281490.HKD","LU2491050154.USD","LU0949170772.SGD","SGXZ31699556.SGD","LU0211326755.USD","LU1506573853.SGD","LU2112291526.USD","IE00BKPKM429.USD","LU0211328371.USD","LU0353189680.USD","IE00BFXG1179.USD","LU0316494557.USD","SG9999014880.SGD","IE0002141913.USD","LU0234572021.USD","LU0011850046.USD","LU2279689827.SGD","LU1066051498.USD","LU1934455277.USD","LU2111349929.HKD","LU1267930573.SGD","LU0965509283.SGD","LU2242649171.HKD","IE00B19Z8W00.USD","IE00B4JS1V06.HKD","SG9999014906.USD","LU0211326839.USD","IE00B19Z3B42.SGD","LU1037948897.HKD","LU1074936037.SGD","LU1814569148.SGD","IE00B19Z9505.USD","LU1037948541.HKD","LU0048584097.USD","600196","LU1854104046.USD","BK4534","LU1720051017.SGD","LU2271345857.HKD","LU0795875086.SGD","IE00BJJMRX11.SGD","LU0266013472.USD","02196","LU2491049909.HKD","IE00BFSS8Q28.SGD","LU1989771016.USD","IE00B775H168.HKD","LU2362540622.SGD","LU1718418525.SGD","LU1791710400.SGD","LU2089283258.USD","SGXZ99366536.SGD","IE00BZ9MQY76.HKD","LU1934455194.USD","LU0094547139.USD","LU0097036916.USD","IE00BFSS7M15.SGD","LU1066051811.HKD","IE00B4R5TH58.HKD","LU0683600562.USD","LU0109391861.USD","LU1066051225.USD","LU0528227936.USD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2592972970","title":"复星医药(600196.SH)控股子公司与Clavis Bio签订合作及选择权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2592972970","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592972970?lang=zh_cn&edition=full","pubTime":"2025-12-18 18:29","pubTimestamp":1766053787,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，2025年12月18日，公司控股子公司复星医药产业与合作方Clavis Bio签订《合作及选择权协议》，根据约定，于约定合作期限内，由复星医药产业与ClavisBio 共同选定靶点并推进针对获选靶点化合物的临床前开发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK0028","BK0096","BK0196","600196","02196","BK0060","BK1515","BK0175","BK0187","BK0188","BK0183","BK1191","BK0239","BK0012"],"gpt_icon":0},{"id":"2592970730","title":"每日卖空追踪 | 复星医药 12月18日卖空量成交5.45万股，卖空比例为1.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592970730","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592970730?lang=zh_cn&edition=full","pubTime":"2025-12-18 16:30","pubTimestamp":1766046626,"startTime":"0","endTime":"0","summary":"复星医药北京时间12月18日，涨0.29%，卖空量成交5.45万股，较上一交易日减少65.06%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218163420a45aa2e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218163420a45aa2e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02196","BK1515","BK1593"],"gpt_icon":0},{"id":"2592973957","title":"诺和诺德：Wegovy®狂飙与9000人裁员背后的GLP-1赛道变局","url":"https://stock-news.laohu8.com/highlight/detail?id=2592973957","media":"摩熵医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592973957?lang=zh_cn&edition=full","pubTime":"2025-12-18 11:07","pubTimestamp":1766027230,"startTime":"0","endTime":"0","summary":"2025年第三季度，诺和诺德的核心产品Wegovy销售额同比狂飙54%，但公司随之而来的决定却让很多人吃了一惊：全球裁员9000人。截至12月10日收盘，诺和诺德股价报收于49.05美元，较前一日上涨5.8%，市值重回2170亿美元以上。诺和诺德在美国的“高增长”依赖的是Wegovy的爆发式放量，而非整体产品线扩张。诺和诺德虽凭Wegovy实现高增长，却因技术代差、市场饱和与研发滞后被迫战略收。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218110738a4597356&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218110738a4597356&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828805.USD","LU2488822045.USD","01801","HK0000165453.HKD","01276","LU1969619763.USD","BK1583","BK1161","LU0455707207.USD","03933","BK1589","02196","LU2097828631.EUR","LU2097828557.USD","LU0502904849.HKD","LU2328871848.SGD","LU2097828474.EUR","LU2097828714.EUR","LU2242644610.SGD"],"gpt_icon":0},{"id":"2592097943","title":"AD药物销售额有望超过140亿美元，这家头部药企今年多次布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2592097943","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592097943?lang=zh_cn&edition=full","pubTime":"2025-12-18 10:35","pubTimestamp":1766025331,"startTime":"0","endTime":"0","summary":"据悉，当前，各大药企正在持续加码AD药物研发。目前，Adel-Y01正在美国食品药品监督管理局批准的研究性新药申请下，进行全球1期临床试验。有报告显示，2025年，全球AD药物销售额为86.7亿美元，预计到2034年，该药物销售额有望达到140.6亿美元。在国内市场，头部药企也在积极引进AD药物，如复星医药2025年12月15日宣布拟出资约14.12亿元控股收购绿谷医药，将获得其用于治疗轻度至中度阿尔茨海默病核心药品甘露特钠胶囊。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218103950a4595745&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218103950a4595745&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1191","BK1515","BK1593"],"gpt_icon":0},{"id":"2592979144","title":"复星高管回应！为何巨额收购“971”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2592979144","media":"药通社","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592979144?lang=zh_cn&edition=full","pubTime":"2025-12-18 10:28","pubTimestamp":1766024898,"startTime":"0","endTime":"0","summary":"12月15日，复星医药公告，拟出资约14.12亿元，收购绿谷（上海）医药科技有限公司51%的股权。2024年，971在中国卖出200多万盒。但各界对971的质疑从未间断。2025年，因绿谷医药未完成上市后确证性临床研究，国家药监局没有重新批准971的上市申请，该药停产。12月15日晚间，复星医药高管在电话会上表示：根据现有临床证据，他们看好971的疗效与前景。接下来，复星医药将推动971的上市后确证性临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218103529a6b06376&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218103529a6b06376&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1593","BK1515","BK1191"],"gpt_icon":0},{"id":"2592979432","title":"三元股份股东复星创泓减持0.62%股份，一致行动人持股比例降至17.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592979432","media":"中访网数据","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592979432?lang=zh_cn&edition=full","pubTime":"2025-12-18 08:02","pubTimestamp":1766016145,"startTime":"0","endTime":"0","summary":"核心事件为复星创泓因自身资金需求，于2025年12月15日至16日期间，通过上海证券交易所集中竞价交易系统减持了公司股份9,364,200股，占公司总股本的比例约为0.62%。本次减持后，复星创泓的持股数量由约5,666.16万股减少至约4,729.74万股，持股比例由3.77%降至3.15%。权益变动后，复星创泓与平闰投资合计持有三元股份约26,657.45万股，占公司总股本的比例由18.37%下降至17.75%，本次变动触及持股比例减少1%的披露刻度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218081248a458c758&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218081248a458c758&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1593","BK1191","BK1515"],"gpt_icon":0},{"id":"2592419995","title":"12月17日复星医药现784.3万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2592419995","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592419995?lang=zh_cn&edition=full","pubTime":"2025-12-17 17:50","pubTimestamp":1765965010,"startTime":"0","endTime":"0","summary":"证券之星消息，12月17日复星医药发生大宗交易，交易数据如下：大宗交易成交价格25.3元，相对当日收盘价折价5.84%，成交31万股，成交金额784.3万元，买方营业部为民生证券股份有限公司北京第一分公司，卖方营业部为中泰证券股份有限公司杭州湖墅南路证券营业部。近三个月该股共发生2笔大宗交易，合计成交9100.0手，折价成交1笔。截至2025年12月17日收盘，复星医药报收于26.87元，上涨0.45%，换手率0.69%，成交量14.57万手，成交额3.89亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700028355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","02196","BK0096","BK0012","BK0060","BK0175","600196","BK0188","BK1593","BK0183","BK0196","BK1515","BK0028","BK1191","BK0239"],"gpt_icon":0},{"id":"2592597916","title":"复星医药超14亿押注绿谷！“九期一”能否走出停产和商业化泥潭？","url":"https://stock-news.laohu8.com/highlight/detail?id=2592597916","media":"药经说","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592597916?lang=zh_cn&edition=full","pubTime":"2025-12-17 17:30","pubTimestamp":1765963839,"startTime":"0","endTime":"0","summary":"日前，复星医药在公告中宣布，控股子公司复星医药产业与绿谷医药及其股东共同签订投资协议，拟出资约14.12亿元控股收购绿谷医药。复星医药在公告中透露，因注册批件到期，2024年11月起，甘露特钠胶囊未开展商业化生产。此外，“九期一”目前仍处于“有条件批准”状态，需完成上市后确证性临床试验并获药监局批准，才能恢复生产销售。复星医药如何通过临床试验再度证明肠道菌群变化与认知改善的直接关联，决定着“九期一”的生命线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217175522a6ad7d3a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217175522a6ad7d3a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02196","BK1515","BK1593"],"gpt_icon":0},{"id":"2592967064","title":"长春高新也老树开花了","url":"https://stock-news.laohu8.com/highlight/detail?id=2592967064","media":"制药在线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592967064?lang=zh_cn&edition=full","pubTime":"2025-12-17 09:37","pubTimestamp":1765935472,"startTime":"0","endTime":"0","summary":"12月15日，长春高新宣布控股子公司长春金赛药业授权其下属全资子公司——上海赛增医疗科技有限公司作为技术许可方，与被许可方Yarrow Bioscience,Inc.签订GenSci098注射液项目独家许可协议。近期开发里程碑款项：预计交付相关临床研究报告及数据等资料后向赛增医疗支付5000万美元。赛增医疗将在后续产品上市后有权获得超过净销售额10%的销售提成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217093755a4548e4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217093755a4548e4f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","02196","BK1191","91272","BK1593"],"gpt_icon":0},{"id":"2592967008","title":"国家中医药管理局原局长于文明被起诉；江西发文支持连锁药店发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2592967008","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592967008?lang=zh_cn&edition=full","pubTime":"2025-12-17 08:04","pubTimestamp":1765929853,"startTime":"0","endTime":"0","summary":"政策将加速行业洗牌，助力连锁药店实现规模化、高质量发展。药械审批国家药监局批准2款创新医疗器械上市近日，国家药监局批准了2款创新医疗器械上市。舆情预警国家中医药管理局原局长于文明涉嫌职务犯罪被移送检察机关审查起诉12月16日消息，经中共中央批准，国家监委对国家中医药管理局原局长于文明严重职务违法问题进行了立案调查。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217080644a45439b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217080644a45439b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1515","BK1191","02196"],"gpt_icon":0},{"id":"2591988977","title":"甘露特钠迎转机，复星医药拟控股绿谷医药推进其上市后临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2591988977","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591988977?lang=zh_cn&edition=full","pubTime":"2025-12-16 17:52","pubTimestamp":1765878774,"startTime":"0","endTime":"0","summary":"12月15日，复星医药宣布，控股子公司复星医药产业与绿谷（上海）医药科技有限公司（“绿谷医药”）及其现有相关股东共同签订相关投资协议，拟出资约14.12亿元控股收购绿谷医药。本次收购完成后，绿谷医药将成为复星医药控股子公司，其核心药品甘露特钠胶囊也将纳入复星医药创新药品管线，主要用于治疗轻度至中度阿尔茨海默病（AD）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512163593128594.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512163593128594.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","02196","BK0183","BK0096","BK1191","BK1515","159938","BK0012","BK0196","600196","09939","BK0028","BK0175","BK1593","BK1161","BK0187","BK0060","BK0188","BK0239"],"gpt_icon":0},{"id":"2591983722","title":"复星医药旗下复星杏脉AI-ROSE系统亮相2025国际机器人支气管镜会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2591983722","media":"复星医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591983722?lang=zh_cn&edition=full","pubTime":"2025-12-16 17:44","pubTimestamp":1765878287,"startTime":"0","endTime":"0","summary":"2025年12月12日至14日，由中国人体健康科技促进会、北京慢性病防治与健康教育研究会共同主办，上海市胸科医院协办的“2025国际机器人支气管镜会议”在上海市举办。会议期间，复星医药旗下复星杏脉携AI-ROSE智能辅助分析系统解决方案参会，同时现场还展出了数字显微图像荧光扫描系统等高端硬件设备，实现从软件智能分析到硬件数字化的完整技术闭环，为呼吸介入诊疗树立新范式。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216182103a6a926ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216182103a6a926ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1191","00656","02196","BK1593"],"gpt_icon":0},{"id":"2591607815","title":"复星医药收购绿谷医药，阿尔兹海默病患者看到曙光？","url":"https://stock-news.laohu8.com/highlight/detail?id=2591607815","media":"读懂财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591607815?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:49","pubTimestamp":1765874940,"startTime":"0","endTime":"0","summary":"　　“阿尔茨海默病药物研发的“死亡谷”里，一款曾被誉为国产创新药希望、又深陷科学争议的明星药物，正在等待它的救赎。”　　12月15日，复星医药宣布收购绿谷医药，其核心产品甘露特钠胶囊也将纳入复星医药创新药品管线。凭借着深厚的全球研发能力和中枢神经领域日益完善的创新药械矩阵，复星医药能否让这款命运多舛的药物重获新生，从而破解现有阿尔茨海默病治疗药物疗效欠佳的困局，成为行业关注的焦点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2025-12-16/doc-inhaysim8510706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0196","09939","BK1161","BK0028","BK0183","BK1515","02196","159938","BK0096","600196","BK0012","BK0060","BK0188","BK0239","BK1191","BK0187","BK0175","BK1593","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":-0.0639},{"period":"1month","weight":-0.0479},{"period":"3month","weight":-0.239},{"period":"6month","weight":0.3866},{"period":"1year","weight":0.5396},{"period":"ytd","weight":0.5221}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0054},{"period":"3month","weight":-0.0322},{"period":"6month","weight":0.0918},{"period":"1year","weight":0.3006},{"period":"ytd","weight":0.2807}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司经营五个分部。制药分部主要从事创新药、成熟医药产品制造和疫苗业务。医疗器械与医学诊断分部主要从事分子诊断、免疫诊断、微生物诊断等医疗美容器械的制造和销售。医疗健康服务分部主要从事线上线下一体化医疗服务平台的经营。医药分销和零售分部主要从事医药产品的批发零售。其他分部从事其他医药相关业务。该公司的产品主要用于肿瘤、免疫、中枢神经等治疗领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.384615,"avgChangeRate":-0.051338},{"month":2,"riseRate":0.769231,"avgChangeRate":0.040467},{"month":3,"riseRate":0.615385,"avgChangeRate":0.048431},{"month":4,"riseRate":0.384615,"avgChangeRate":0.03076},{"month":5,"riseRate":0.461538,"avgChangeRate":0.035265},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.026545},{"month":7,"riseRate":0.615385,"avgChangeRate":0.027595},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.041651},{"month":9,"riseRate":0.461538,"avgChangeRate":0.011609},{"month":10,"riseRate":0.461538,"avgChangeRate":0.020359},{"month":11,"riseRate":0.428571,"avgChangeRate":0.034495},{"month":12,"riseRate":0.5,"avgChangeRate":0.020332}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}